Moffitt Cancer Center researchers target specific protein associated with poor survival and treatment

(H. Lee Moffitt Cancer Center & Research Institute) Glioblastoma multiformeis a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed. Moffitt Cancer Center researchers recently reported that expression of the protein BIRC3 is associated with poor survival and recurrent disease in GBM patients; and...